Systemic Fibrotic Diseases

Targeting shared biological pathways that drive fibrosis across multiple organs 

Understanding The Disease
What are systemic fibrotic diseases?
Systemic fibrotic diseases are conditions in which excessive scarring affects multiple organs and tissues throughout the body. Unlike organ-specific fibrosis, these diseases involve widespread activation of fibrotic pathways that can impact the lungs, heart, liver, kidneys, skin, and other vital organs simultaneously.

These complex conditions share common molecular mechanisms, suggesting that therapies targeting fundamental fibrotic pathways could benefit patients across multiple organ systems.
Disease We Address
Multi-Organ Fibrotic Conditions
Our research focuses on systemic diseases where fibrosis affects multiple organ systems.

Scleroderma

Autoimmune disease-causing widespread fibrosis of skin and internal organs including lungs, heart, kidneys, and digestive tract, leading to progressive organ dysfunction

Nephrogenic Systemic Fibrosis

Rare systemic disorder characterized by fibrosis of skin, joints, and internal organs, typically occurring in patients with severe kidney disease.

Chronic Graft vs. Host Disease

Complication following stem cell or bone marrow transplant where donor immune cells attack recipient tissues, causing chronic inflammation and fibrosis across multiple organs.

Atherosclerosis

Progressive disease involving fibrotic plaque buildup in arterial walls throughout the body, restricting blood flow and increasing risk of heart attack and stroke.
Our Research Efforts
Exploring A Platform Approach to Systemic Fibrosis
We are developing therapies with a potential to target the core biological pathways driving fibrosis across multiple organ systems.
 

Shared Pathway Targeting

Focusing on fundamental fibrotic mechanisms common across different organs, rather than organ-specific approaches.

 

Multi-Organ Efficacy

Developing platform therapies designed to halt fibrosis progression in multiple organ systems simultaneously.

 

Disease Modification

Pursuing disease-modifying therapies that address root causes rather than merely managing symptoms.

Learn More About Our Science
Discover the innovative platform technology driving our systemic fibrosis research and development programs.
IMPORTANT NOTICE
We are an early stage company developing a research pipeline of products addressing fibrotic diseases. The product candidates described on this website are in various stages of development and have not been approved or determined to be safe or effective by the U.S. Food and Drug Administration or any comparable regulatory authority. Nothing on this website is intended to suggest the safety, efficacy, or commercial availability of any product candidate in the United States.